|
Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen Clinical research trials and Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen. Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen clinical trial. Human subjects often obtain the finest healthcare possible for their Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen
Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen
For Condition: Human Immunodeficiency Virus
Status: No longer recruiting
Sponsor(s): Pfizer ,
Synopsis: This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Male or female at least 18 years old - HIV RNA level >1000 copies/mL at screening - CD4 >50 cells/uL at screening - Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen - Patient has adequate hematology tests (absolute neutrophil count >1000/uL, Platelets>75,000uL, hemoglobin 9g/L) - Patient has adequate renal function (serum creatinine of <1.5 upper limit of normal) - Patient has adequate liver function (AST, ALT, and bilirubin < 2.5 upper limit of normal) Exclusion Criteria: - Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was <50 copies) This exception does not include Viracept - Women who are pregnant or lactating
Total Enrollment: 150
Location and Contact Information:
Pfizer Investigational Site
Cincinnati, Ohio, 45267
United States
Pfizer Investigational Site
Tampa, Florida, 33602
United States
Pfizer Investigational Site
Ft. Lauderdale, Florida, 33311
United States
Pfizer Investigational Site
Brooklyn, New York, 11203
United States
Pfizer Investigational Site
Brescia, , 25123
Italy
Pfizer Investigational Site
Houston, Texas, 77009
United States
Pfizer Investigational Site
Cape Town, , 7925
South Africa
Pfizer Investigational Site
Lyon, Cedex 3, 69437
France
Pfizer Investigational Site
Jonesboro, Georgia, 30236
United States
Pfizer Investigational Site
Austin, Texas, 78705
United States
Pfizer Investigational Site
Atlanta, Georgia, 30339-3915
United States
Pfizer Investigational Site
Beverly Hills, California, 90211
United States
Pfizer Investigational Site
Jackson, Mississippi, 39202
United States
Pfizer Investigational Site
Galveston, Texas, 77555
United States
Pfizer Investigational Site
Long Beach, California, 90813
United States
Pfizer Investigational Site
Safety Harbor, Florida, 34695
United States
Pfizer Investigational Site
Stony Brook, New York, 11794
United States
Pfizer Investigational Site
Akron, Ohio, 44304
United States
Pfizer Investigational Site
Nantes, , 44035
France
Pfizer Investigational Site
West Hollywood, California, 90069
United States
Pfizer Investigational Site
Paris, Cedex 10, 74575
France
Pfizer Investigational Site
Pretoria North, , 0182
South Africa
Pfizer Investigational Site
Chicago, Illinois, 60611
United States
Pfizer Investigational Site
Tucker, Georgia, 30084
United States
Pfizer Investigational Site
Johannesburg, , 2193
South Africa
Pfizer Investigational Site
Winston Salem, North Carolina, 27157-1042
United States
Pfizer Investigational Site
Bilbao, Vizcaya, 48903
Spain
Pfizer Investigational Site
San Francisco, California, 94115
United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19107
United States
Pfizer Investigational Site
Cape Town, , 7925
South Africa
Pfizer Investigational Site
Lyon, Cedex 02, 69288
France
Pfizer Investigational Site
Portland, Oregon, 97209
United States
Pfizer Investigational Site
Roma, , 00149
Italy
Pfizer Investigational Site
Port Elizabeth, , 6001
South Africa
Pfizer Investigational Site
Cordoba, , 14004
Spain
Pfizer Investigational Site
Portland, Oregon, 97210
United States
Pfizer Investigational Site
Miami, Florida, 33137
United States
Pfizer Investigational Site
Johannesburg, , 02198
South Africa
Pfizer Investigational Site
Johannesburg, , 2008
South Africa
Pfizer Investigational Site
Cape Town, , 7405
South Africa
Pfizer Investigational Site
PIETERMARITZBURG, , 3201
South Africa
Pfizer Investigational Site
Barcelona, , 08035
Spain
Pfizer Investigational Site
Soweto, , 2013
South Africa
Pfizer Investigational Site
Ulm, Bavaria, 89070
Germany
Pfizer Investigational Site
San Francisco, California, 94121
United States
Pfizer Investigational Site
Dallas, Texas, 75246
United States
Pfizer Investigational Site
Milano, , 20127
Italy
Pfizer Investigational Site
Dallas, Texas, 75246
United States
Pfizer Investigational Site
Milano, , 20157
Italy
Pfizer Investigational Site
New York City, New York, 10003
United States
Pfizer Investigational Site
Newport Beach, California, 92663
United States
Pfizer Investigational Site
Huntersville, North Carolina, 28078
United States
Pfizer Investigational Site
Wichita, Kansas, 67214
United States
Pfizer Investigational Site
Baracaldo, Bilbao, Vizcaya, 48903
Spain
Additional Information:
Study ID Numbers: A4311002;
Study Start Date: August 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00051844
Other Human Immunodeficiency Virus Studies:
1. Relaxation Response with Acupuncture for HIV Patients
2. Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen
Related Studies:
Other Human Immunodeficiency Virus Clinical Trials
Other Clinical Trials
Other Brescia Clinical Trials
Capravirine (AG1549) in Combination with Viracept and Two NRTIs in HIV infected Patients Who Failed an Initial NNRTI Containing Regimen
|
|
|
|
|
|
|
|